跳至主要内容
临床试验/NCT06018415
NCT06018415已完成不适用

Effects of Early and Late Time-restricted Eating on Overweight Adults With Metabolic Syndrome

First Affiliated Hospital Xi'an Jiaotong University1 个研究点 分布在 1 个国家目标入组 103 人开始时间: 2024年5月7日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
103
试验地点
1
主要终点
Changes in abdominal fat area

研究概览

简要总结

Investigators aim to compare the effects of early and late time-restricted feeding on overweight adults with metabolic syndrome

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age from 18 to 65 years
  • Body mass index (BMI): 24.0-40.0 kg/m2
  • Diagnosed with metabolic syndrome (i.e., more than 3 abnormal findings out of 5):
  • Waist circumference ≥ 90 cm (men) or ≥ 80 cm (women).
  • Elevated triglyceride (TG) (use of lipid-lowering medication is an alternate indicator) ≥ 150 mg/dL (1.7 mmol/L).
  • Reduced high-density lipoprotein cholesterol (HDL-c) (use of lipid-lowering medication is an alternate indicator) < 40 mg/dL (1.0 mmol/L) in males < 50 mg/dL (1.3 mmol/L) in females.
  • Elevated blood pressure (use of antihypertensive medication is an alternate indicator). Systolic blood pressure (SBP) ≥ 130 and/or diastolic blood pressure (DBP) ≥ 85 mmHg.
  • Elevated fasting blood glucose (FBG) (used of hypoglycemic medications is an alternate indicator) ≥ 100 mg/dL (5.6 mmol/L).

排除标准

  • Unstable weight (change > 10% current body weight) for 3 months prior to the study
  • Pregnant or breast-feeding
  • Night shift workers
  • History of major diseases or related diseases, such as cancer, inflammatory disease, chronic obstructive pulmonary disease and major adverse cardiovascular event
  • Active viral hepatitis, acquired immune deficiency syndrome, syphilis and other sexually transmitted diseases, tuberculosis and other infectious diseases
  • Being treated with antibiotics or corticosteroids
  • Current participate in other weight-management program, current on a prescribed diet for special disease or current on any drugs that effect appetite
  • The researcher deemed it inappropriate to participate in the experimenter.

结局指标

主要结局

Changes in abdominal fat area

时间窗: 0-week; 6-week and 12-week

Abdominal fat area is measured using bioelectrical impedance analysis (OMRON MEDICAL Beijing Co., Ltd. DUALSCAN, HDS-2000) to the nearest 1 cm2.

Changes in body weight

时间窗: 0-week; 6-week and 12-week

Body weight is assessed at the research center with the participants without shoes and in light clothing using a digital scale (OMRON MEDICAL Beijing Co., Ltd. HNH-318) to the nearest 0.1 kg.

次要结局

  • Changes in body composition ( body fat mass)(0-week and 12-week)
  • Changes in body composition (body muscle mass)(0-week and 12-week)
  • Changes in glycemic control(0-week; 6-week and 12-week (glucose and insulin)0-week and 12-week (HbA1c))
  • Changes in hemoglobin A1c (HbA1c)(0-week; 6-week and 12-week (glucose and insulin)0-week and 12-week (HbA1c))
  • Changes in total cholesterol, triglyceride (TG), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c)(0-week; 6-week and 12-week)
  • Changes in uric acid (UA)(0-week; 6-week and 12-week)
  • Changes in blood pressure.(0-week; 6-week and 12-week)
  • Changes in total cholesterol, triglyceride (TG), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c)(0-week; 6-week and 12-week)
  • Changes in uric acid (UA)(0-week; 6-week and 12-week)
  • Changes in blood pressure.(0-week; 6-week and 12-week)
  • Changes in body composition ( body fat mass)(0-week and 12-week)
  • Changes in body composition (body muscle mass)(0-week and 12-week)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验